

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)

Name of Patentee	Foghorn Therapeutics Inc.	Docket Number (Optional)	51121-027005
Patent Number	11,560,381	Date Patent Issued	January 24, 2023
Title of Invention			
COMPOUNDS AND USES THEREOF			

I hereby disclaim the following complete claims in the above identified patent:

1-12


The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, Assignee of 100% of the rights based on the assignment recorded at Reel: where assignment is recorded): 060464, Frame: 0796

The fee for this disclaimer is set forth in 37 CFR 1.20(d).

- ☒ Patentee claims small entity status. See 37 CFR 1.27.
- ☒ Small entity status has already been established in this case, and is still proper.
- ☐ A check in the amount of the fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 03-2095.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signed at Cambridge, MA USA State of MA
 this 17th day of January 2024.


 Signature

Registration Number, if applicable

Adrian Gottschalk, President and CEO of Foghorn Therapeutics Inc.
 Typed or printed name of patentee/ attorney or agent of record

617-586-3100
 Telephone Number

500 Technology Square, Suite 700

Address

Cambridge, MA 02139

City, State, Zip Code or Foreign Country as applicable